Nrx pharmaceuticals announces definitive purchase agreement for preferred shares at $0.40 per share

Nrx pharmaceuticals received approximately $1.2 million in cash from existing investors preferred shares to sold at $0.40; shares convert to one common share and one common warrant ($0.40/ strike) after six months share purchase will assist the company in development of nrx-101 in suicidal bipolar depression and chronic pain and general corporate purposes radnor, pa. , aug. 29, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced that it entered into a definitive purchase agreement subject to standard closing conditions with accredited investors to purchase 3,000,000 shares of preferred stock at $0.40 per share, which will convert, after six (6) months into 3,000,000 common shares and 3,000,000 warrants to purchase common stock at a purchase price of $0.40 per share; the term on these warrants is five (5) years.
NRXP Ratings Summary
NRXP Quant Ranking